Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217366 | 1.00 | USP2 (0.31) | USP2 | |
| SCHEMBL3410841 | 0.80 | — | — | |
| SCHEMBL26322455 | 0.78 | — | — | |
| SCHEMBL26322458 | 0.78 | — | — | |
| SCHEMBL26324362 | 0.78 | GRIK1 (0.33) | — | |
| SCHEMBL25891755 | 0.78 | — | — | |
| SCHEMBL10056594 | 0.71 | — | — | |
| SCHEMBL15369599 | 0.71 | — | — | |
| SCHEMBL28913703 | 0.71 | — | — | |
| SCHEMBL28913714 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173824-B2 | Process for producing vitamin D derivative using convergent method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173824-B2 | Process for producing vitamin D derivative using convergent method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100217020-A1 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100217020-A1 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7524980-B2 | vitamin D3 antagonist activity; treating Paget's disease, bone diseases, hypercalcemia or osteoporosis; e.g. 1 alpha,25-dihydroxyvitamin D3-26 23-lactam, N-(p-methoxy)benzyl | TEIJIN PHARMA LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217020-A1 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD | CYP2R1, CYP24A1, VDR | USP2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.